NARROW-SPECTRUM ANTIBACTERIAL ANTIBIOTICS TARGETING SPECIFIC TYPES OF BACTERIA THAT SYNTHESIZES MENAQUINONE THROUGH AN ALTERNATIVE PATHWAY VIA FUTALOSINE OR 6-AMINODEOXYFUTALOSINE AS AN INTERMEDIATE.
| 外国特許コード | F160008799 |
|---|---|
| 整理番号 | (S2014-1273-N0) |
| 掲載日 | 2016年8月4日 |
| 出願国 | 世界知的所有権機関（ＷＩＰＯ） |
| 国際出願番号 | 2015JP004928 |
| 国際公開番号 | WO 2016051767 |
| 国際出願日 | 平成27年9月29日(2015.9.29) |
| 国際公開日 | 平成28年4月7日(2016.4.7) |
| 優先権データ |
|
| 発明の名称 （英語） | NARROW-SPECTRUM ANTIBACTERIAL ANTIBIOTICS TARGETING SPECIFIC TYPES OF BACTERIA THAT SYNTHESIZES MENAQUINONE THROUGH AN ALTERNATIVE PATHWAY VIA FUTALOSINE OR 6-AMINODEOXYFUTALOSINE AS AN INTERMEDIATE. |
| 発明の概要（英語） | Alternative menaquinone biosynthetic pathway via futalosine or 6-aminodeoxyfutalosine as an intermediate (futalosine pathway) is an attractive target for new narrow-spectrum antimicrobial agents. Siamycin I and fatty acids were provided as selective antimicrobial activity against bacteria such as Helicobacter and Campylobacter, which depend on the futalosine pathway to grow. Specifically, siamycin I and omega-3 polyunsaturated fatty acids inhibited the colonization of H. pylori in vivo and thus siamycin I and omega-3 polyunsaturated fatty acids could be a new narrow-spectrum antibiotic for Helicobacter and Campylobacter |
| 特許請求の範囲（英語） |
[claim1] 1. Siamycin I or a fatty acid for the treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject, wherein the bacterium synthesize menaquinone through the futalosine pathway, and wherein the siamycin I or a fatty acid inhibits the futalosine pathway in the treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject. [claim2] 2. Siamycin I or a fatty acid for inhibiting synthesis of menaquinone through the futalosine pathway by a bacterium in a subject who is infected by the bacterium comprising administration of siamycin I or a fatty acid to the subject, wherein the bacterium synthesize menaquinone through the futalosine pathway, and wherein the siamycin I or a fatty acid inhibits the futalosine pathway. [claim3] 3. The Siamycin I or a fatty acid of claim 1 or 2, wherein the bacterium is selected from a group consisting of genus of Helicobacter, Campylobacter, Wolinella and Streptomyces. [claim4] 4. The Siamycin I or a fatty acid of claim 1 or 2, wherein the bacterium is a Helicobacter pylori, [claim5] 5. The Siamycin I or a fatty acid of claim 1 or 2, wherein the fatty acid is at least one fatty acid that is selected from a group consisting of omega-3 fatty acids, α-linolenic acid, EPA, DHA, oleic acid, linoleic acid, and arachidonic acid. [claim6] 6. A method for the treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject comprising administration of siamycin I or a fatty acid to the subject, wherein the bacterium synthesize menaquinone through the futalosine pathway, and wherein the siamycin I or a fatty acid inhibits the futalosine pathway. [claim7] 7. A method for inhibiting synthesis of menaquinone through the futalosine pathway by a bacterium in a subject who is infected by the bacterium, comprising administration of siamycin I or a fatty acid to the subject, wherein the bacterium synthesize menaquinone through the futalosine pathway, and wherein the siamycin I or a fatty acid inhibits the futalosine pathway. [claim8] 8. A pharmaceutical composition comprising siamycin I or a fatty acid for use in treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject, wherein the bacterium synthesize menaquinone through the futalosine pathway, and wherein the siamycin I or a fatty acid inhibits the futalosine pathway in the treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject. [claim9] 9. A pharmaceutical composition comprising siamycin I or a fatty acid for use in inhibiting synthesis of menaquinone through the futalosine pathway by bacterium in a subject who is infected by the bacterium comprising administration of siamycin I or a fatty acid to the subject, wherein the bacterium synthesize menaquinone through the futalosine pathway, and wherein the siamycin I or a fatty acid can inhibit the futalosine pathway. [claim10] 10. A method for the prevention of bacterium propagation in food, feedstuff or drinking water that contain siamycin I or a fatty acid. [claim11] 11. The method of claim 10, wherein feedstuff or drinking water application in combating Campylobacter propagation in poultry. |
|
|
|
|
| 国際特許分類(IPC) |
|
| 指定国 |
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW EAPO: AM AZ BY KG KZ RU TJ TM EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG |
『 NARROW-SPECTRUM ANTIBACTERIAL ANTIBIOTICS TARGETING SPECIFIC TYPES OF BACTERIA THAT SYNTHESIZES MENAQUINONE THROUGH AN ALTERNATIVE PATHWAY VIA FUTALOSINE OR 6-AMINODEOXYFUTALOSINE AS AN INTERMEDIATE. 』に関するお問合せ
- 学校法人北里研究所 北里大学 知的資産センター
- URL: https://www.kitasato-u.ac.jp/jp/index.html
-
E-mail:
- Address: 〒252-0373 神奈川県相模原市南区北里1丁目15番1
- TEL: 042-778-9756
- FAX: 042-778-9761
※ 同じキーワードでJ-STORE内を検索することが出来ます。→ J-STORE内を検索
